ZA201008027B - Substituted thiophenecarboxamides as ikk-beta serine-,threonine-protein kinase inhibitors - Google Patents

Substituted thiophenecarboxamides as ikk-beta serine-,threonine-protein kinase inhibitors

Info

Publication number
ZA201008027B
ZA201008027B ZA2010/08027A ZA201008027A ZA201008027B ZA 201008027 B ZA201008027 B ZA 201008027B ZA 2010/08027 A ZA2010/08027 A ZA 2010/08027A ZA 201008027 A ZA201008027 A ZA 201008027A ZA 201008027 B ZA201008027 B ZA 201008027B
Authority
ZA
South Africa
Prior art keywords
ikk
threonine
protein kinase
kinase inhibitors
beta serine
Prior art date
Application number
ZA2010/08027A
Other languages
English (en)
Inventor
David Festus Charles Moffat
Stephen John Davies
Original Assignee
Chroma Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0807642A external-priority patent/GB0807642D0/en
Priority claimed from GB0815550A external-priority patent/GB0815550D0/en
Application filed by Chroma Therapeutics Ltd filed Critical Chroma Therapeutics Ltd
Publication of ZA201008027B publication Critical patent/ZA201008027B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
ZA2010/08027A 2008-04-26 2010-11-09 Substituted thiophenecarboxamides as ikk-beta serine-,threonine-protein kinase inhibitors ZA201008027B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0807642A GB0807642D0 (en) 2008-04-26 2008-04-26 IKK- serine-threonine protein kinase inhibitors
GB0815550A GB0815550D0 (en) 2008-08-27 2008-08-27 IKK-beta serine-threonine protein kinase inhibitors
PCT/GB2009/001051 WO2009130475A1 (en) 2008-04-26 2009-04-23 Substituted thiophenecarboxamides as ikk-beta serine-, threonine-protein kinase inhibitors

Publications (1)

Publication Number Publication Date
ZA201008027B true ZA201008027B (en) 2011-07-27

Family

ID=40786701

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2010/08027A ZA201008027B (en) 2008-04-26 2010-11-09 Substituted thiophenecarboxamides as ikk-beta serine-,threonine-protein kinase inhibitors

Country Status (13)

Country Link
US (1) US20110046210A1 (enExample)
EP (1) EP2285797A1 (enExample)
JP (1) JP2011518817A (enExample)
KR (1) KR20110020784A (enExample)
CN (1) CN102036980A (enExample)
AU (1) AU2009239772A1 (enExample)
BR (1) BRPI0911480A2 (enExample)
CA (1) CA2722660A1 (enExample)
EA (1) EA201001708A1 (enExample)
IL (1) IL208654A0 (enExample)
MX (1) MX2010011643A (enExample)
WO (1) WO2009130475A1 (enExample)
ZA (1) ZA201008027B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012046793A1 (ja) * 2010-10-07 2012-04-12 参天製薬株式会社 ウレイド基とアミノカルボニル基を置換基として有するチオフェン誘導体を有効成分として含有する新規ｊａｋ３阻害剤
GB201211310D0 (en) 2012-06-26 2012-08-08 Chroma Therapeutics Ltd CSF-1R kinase inhibitors
CN104781235B (zh) 2012-10-17 2016-12-21 色品疗法有限公司 N-[2-{4-[6-氨基-5-(2,4-二氟苯甲酰)-2-氧代吡啶-1(2h)-基]-3,5-二氟苯基}乙基]-l-丙氨酸叔丁酯或其盐、水合物或溶剂合物
PT2953942T (pt) 2013-02-06 2018-01-17 Bayer Cropscience Ag Derivados de pirazol substituídos com halogéneo como agentes pesticidas
GB201713975D0 (en) 2017-08-31 2017-10-18 Macrophage Pharma Ltd Medical use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102616D0 (sv) * 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
SE0300092D0 (sv) * 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
WO2008002246A1 (en) * 2006-06-28 2008-01-03 Astrazeneca Ab A pharmaceutical composition comprising an ikk2 inhibitor and a second active ingrdient.
US8106091B2 (en) * 2006-11-01 2012-01-31 Chroma Therapeutics Ltd. Inhibitors of IKK-beta serine-threonine protein kinase
BRPI0718056A2 (pt) * 2006-11-01 2013-11-05 Chroma Therapeutics Ltd Inibidores da proteína cinase ikk-beta serina-treonina

Also Published As

Publication number Publication date
JP2011518817A (ja) 2011-06-30
EP2285797A1 (en) 2011-02-23
KR20110020784A (ko) 2011-03-03
EA201001708A1 (ru) 2011-06-30
MX2010011643A (es) 2010-11-30
CN102036980A (zh) 2011-04-27
BRPI0911480A2 (pt) 2018-04-03
US20110046210A1 (en) 2011-02-24
WO2009130475A1 (en) 2009-10-29
AU2009239772A1 (en) 2009-10-29
CA2722660A1 (en) 2009-10-29
IL208654A0 (en) 2010-12-30

Similar Documents

Publication Publication Date Title
ZA201102423B (en) Imidazopyridazinecarbonitriles useful as kinase inhibitors
IL257083B (en) The history of phosphorus as kinase inhibitors
ZA201008808B (en) Novel phenylpyrazinones as kinase inhibitors
ZA201004942B (en) Ptrrolopyrazine kinase inhibitors
IL206358A0 (en) Pyrrolopyrazine kinase inhibitors
IL209258A0 (en) Pyrrolopyridines as kinase inhibitors
ZA201204246B (en) Kinase inhibitors
ZA201203842B (en) Kinase inhibitors
IL210573A0 (en) Compounds as kinase inhibitors
IL218271A0 (en) Heterocyclic compounds as janus kinase inhibitors
IL213464A0 (en) Kinase inhibitor compounds
PT2231642E (pt) Pirimidinas como inibidores de quinase
ZA201202776B (en) Imidazole derivatives as casein kinase inhibitors
IL220205A0 (en) Heterocyclic compounds as janus kinase inhibitors
ZA201008878B (en) Naphthyridiniones as aurora kinase inhibitors
ZA201008027B (en) Substituted thiophenecarboxamides as ikk-beta serine-,threonine-protein kinase inhibitors
GB0914726D0 (en) Kinase inhibitors
GB0807908D0 (en) ikk-beta serine-theronine protein kinase inhibitors
ZA201004903B (en) Pyrrolopyrazine kinase inhibitors
GB0815550D0 (en) IKK-beta serine-threonine protein kinase inhibitors